Neogen Corporation (NEOG) latest stock news and headlines
This article provides a compilation of recent news and headlines concerning Neogen Corporation (NEOG), including its stock performance, upcoming earnings call, and analyses from various financial outlets. It highlights the company's YTD stock rally, discusses analyst estimates for its Q1 potential, and lists several articles evaluating its stock value and market position. The financial data indicates NEOG's strong year-to-date and one-year returns, significantly outperforming the S&P 500, despite a three-year decline.
Neogen (NASDAQ:NEOG) Upgraded to Strong-Buy at Wall Street Zen
Neogen (NASDAQ:NEOG) has been upgraded to a "strong-buy" rating by Wall Street Zen, while other analysts maintain a "Hold" consensus with an average price target of $12.67. The company's stock opened at $12.15, and it recently surpassed quarterly earnings expectations with $0.09 EPS on $225.3 million in revenue. Institutional ownership of Neogen is high at 96.73%, with major investors increasing their positions.
20,558 options and 9,804 stock units go to Neogen (NEOG) director Ronald D. Green.
Neogen Corp. director Ronald D. Green received equity awards on October 1, 2026, consisting of 20,558 options to buy common stock and 9,804 restricted stock units (RSUs). The options have an exercise price of $12.24 and expire on October 1, 2036. Both the options and RSUs will vest in equal annual installments over the first three anniversary dates of their grants.
A director receives 20,558 options at NEOGEN (NEOG), with awards vesting in three annual installments.
NEOGEN director Avi Pelossof received an award of 20,558 options with a $12.24 exercise price and 9,804 restricted stock units on October 1, 2026. Both awards will vest in equal annual installments over the first three grant anniversaries, with the options expiring on October 1, 2036. This information was disclosed in a Form 4 SEC filing, detailing the insider trading activity.
Form 4 Neogen Corporation For: 2 October By Investing.com
This article is a brief announcement regarding a Form 4 filing for Neogen Corporation on October 2nd. It provides a link to view the associated comments and notes the company's stock symbol as NEOG, which experienced a slight decrease.
A director receives 20,558 options at $12.24 plus restricted stock awards from Neogen (NEOG).
Neogen Corp. director Rafael A. Rodriguez was granted 20,558 rights to buy common shares at an exercise price of $12.24 and 9,804 restricted stock units on October 1, 2026. Both the options and restricted stock units are set to vest in equal annual installments over the first three anniversary dates of the grants, with the rights to buy common stock expiring on October 1, 2036. Following these awards, Rodriguez's reported holdings include 20,558 rights to buy common stock and 30,625 restricted stock units.
A 9,804-unit stock grant goes to Neogen (NEOG) director Catherine E. Woteki.
Neogen Corp. (NEOG) director Catherine E. Woteki was awarded 20,558 stock options and 9,804 restricted stock units on October 1, 2026. The options have an exercise price of $12.24 per share and expire on October 1, 2036. Both the options and RSUs will vest in equal annual installments over the first three anniversary dates of the grants.
Form 4 Neogen Corporation For: 2 October
The article is a financial market update from Investing.com, specifically reporting on a Form 4 filing for Neogen Corporation on October 2nd. It is a brief, one-line announcement that primarily serves as a placeholder or a headline for regulatory filing news. The main content of the page includes various financial market data, popular news articles, and promotional content from Investing.com.
A 9,804-unit stock grant goes to Neogen (NEOG) director Aashima Gupta alongside 20,558 options.
Neogen (NEOG) director Aashima Gupta was granted 20,558 stock options and 9,804 restricted stock units (RSUs) on October 1, 2026. Both awards vest in equal annual installments over the first three grant anniversaries, with the options expiring on October 1, 2036. Following this RSU award, Gupta's reported holdings of restricted stock units total 37,594 shares.
Neogen (NEOG) grants Capello 9,804 stock units alongside 20,558 options.
Neogen Corp. director Jeffrey D. Capello was granted 20,558 options to buy common stock and 9,804 restricted stock units on October 1, 2026. The options have an exercise price of $12.24 per share and expire on October 1, 2036. Both award types will vest in equal annual installments over the first three anniversary dates of the grants.
Unlocking Q1 Potential of Neogen (NEOG): Exploring Wall Street Estimates for Key Metrics
Wall Street analysts anticipate Neogen (NEOG) to report a 25% year-over-year increase in Q1 earnings, reaching $0.05 per share, with revenues expected to be $208.09 million, a 0.5% decrease. Key metric estimates include varied growth in food safety segments and some declines in animal safety segments. The stock currently holds a Zacks Rank #2 (Buy) and has outperformed the S&P 500 recently.
NEOG Maintained by Guggenheim -- Price Target Raised to $14.00
Guggenheim has maintained a "Buy" rating for Neogen (NEOG) and increased its price target from $12.00 to $14.00, reflecting confidence in the company's future performance. Despite this, GuruFocus indicates NEOG is currently overvalued with a GF Value™ of $11.19 against a current price of $12.73, and notes a low growth rank, suggesting caution for investors. Insider activity shows modest buying without selling, while gurus have generally maintained or added to their stakes.
Guggenheim maintains Buy rating on Neogen, $14 price target
Guggenheim has reiterated its Buy rating on Neogen (NEOG) with a $14.00 price target, suggesting a 10.0% upside from its recent closing price. The positive outlook is attributed to Neogen's operational improvements through executive team changes and disciplined execution, as well as its strong market growth potential in both Food Safety and Animal Safety segments.
Why Neogen (NEOG) Stock Is Falling Today
Neogen (NEOG) stock fell 6.3% today without a clear company-specific catalyst, suggesting investor caution ahead of its upcoming Q1 fiscal 2027 earnings release on October 6, 2026, and an investor day on October 7, 2026. The stock's notable short-interest profile may also be amplifying volatility. Insider trading data shows the CEO purchased shares recently, while institutional investors show mixed activity with some significantly increasing and others decreasing their positions.
Why is Neogen Stock Trading Lower on Tuesday?
Neogen stock is trading lower due to a formal warning letter issued by the FDA concerning severe microbiological contamination in its HYCOAT hyaluronate sodium sterile solution, linked to numerous equine fatalities. Federal investigations revealed viable fungal species in the product and widespread unsanitary conditions at the contract manufacturing facility. Neogen Vet must submit a corrective action plan within 15 working days to avoid further regulatory action.
Neogen Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Neogen Corporation is set to release its Q1 earnings after the closing bell on Tuesday, October 6. Analysts anticipate quarterly earnings of 5 cents per share on $208.18 million in revenue. The article highlights recent forecast changes from top analysts, including upgrades and price target increases from Piper Sandler, Guggenheim, and CJS Securities.
Neogen Corporation (NEOG) stock price, news, quote and history
This article provides a detailed overview of Neogen Corporation (NEOG), including its current stock price, financial statistics, historical data, and recent news. It highlights the company's business in food and animal safety, its financial performance with an emphasis on revenue and earnings trends, and analyst insights regarding price targets and recommendations. The piece serves as a comprehensive resource for investors interested in NEOG.
ETFs Investing in Neogen Corp Stocks
This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold Neogen Corp (NEOG) stocks, sorted by market value. It details various passive and active ETFs, primarily focusing on small-cap and health technology sectors, offering investors diverse options with varying expense ratios and performance metrics. The data helps investors identify funds that include NEOG, providing insights into potential investment opportunities and risk diversification through ETFs.
Neogen Corporation (NEOG) stock price, news, quote and history
Neogen Corporation (NEOG) stock is currently trading at $13.66, up 0.66% at the close of September 24th. The company, which specializes in food and animal safety products, has seen significant year-to-date and 1-year returns of 95.42% and 152.03% respectively. Analysts have an average target price of $13.33 for NEOG, with recent ratings including an upgrade to Overweight by Piper Sandler.
Bank of America Corp DE Makes New $28.28 Million Investment in Neogen Corporation $NEOG
Bank of America Corp DE has made a new $28.28 million investment in Neogen Corporation (NASDAQ:NEOG), acquiring 3.15 million shares. This move comes as institutional investors collectively own 96.73% of Neogen. Despite mixed analyst sentiment and flat year-over-year revenue, Neogen recently beat earnings expectations, reporting $0.09 EPS on $225.3 million in revenue.
First-quarter results are scheduled for Oct. 6. Neogen’s call starts at 4:30 p.m.
Neogen Corporation announced it will release its first-quarter earnings after the market closes on October 6, 2026. Company executives will host a webcast and conference call at 4:30 p.m. Eastern time to discuss the financial results. Investors can access the live webcast and a replay through Neogen’s Investor Relations webpage.
Neogen Corporation stock hits 52-week high at 12.86 USD
Neogen Corporation (NEOG) stock recently hit a 52-week high of $12.86, representing a significant 135.16% increase over the past year. This surge is attributed to strong investor confidence and impressive financial performance, including exceeding fiscal Q4 earnings and revenue expectations. Piper Sandler also upgraded the stock, raising its price target to $14.00, further validating the company's growth trajectory under new management.
Neogen Announces First-Quarter Earnings Release Date
Neogen Corporation (NASDAQ: NEOG) announced that it will release its first-quarter earnings after market close on October 6, 2026. The company will host a webcast and conference call at 4:30 p.m. Eastern time to discuss the financial results, with details provided for accessing both the live event and a replay.
Neogen Announces First-Quarter Earnings Release Date
Neogen Corporation (NASDAQ: NEOG) will release its first-quarter earnings after the market closes on October 6, 2026. The company will also host a webcast and conference call at 4:30 p.m. Eastern time to discuss the financial results, with replay information provided for those unable to attend live.
Neogen Announces First-Quarter Earnings Release Date
Neogen Corporation (NASDAQ: NEOG) has announced that it will release its first-quarter earnings after the market closes on October 6, 2026. The company will also host a webcast and conference call at 4:30 p.m. Eastern time to discuss the financial results, with details provided for accessing both the call and webcast. A replay will be available on Neogen's Investor Relations website following the event.
Neogen Corporation (NASDAQ:NEOG) Given Consensus Rating of "Hold" by Analysts
Neogen Corporation (NASDAQ:NEOG) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $12.00. The company recently reported quarterly earnings of $0.09 per share, exceeding consensus estimates, and revenue of $225.3 million. Institutional investors own a significant 96.73% of Neogen's shares.
Squarepoint Ops LLC Buys New Position in Neogen Corporation $NEOG
Squarepoint Ops LLC has acquired a new stake in Neogen Corporation (NASDAQ:NEOG) during the second quarter, purchasing 293,880 shares valued at approximately $2.64 million. This move comes as Neogen exceeded its quarterly earnings expectations, reporting $0.09 EPS against a $0.06 consensus, and analysts hold a mixed but improving sentiment, with an average "Hold" rating and a $12.00 price target. Institutional investors currently own 96.73% of the company's stock.
Neogen (NASDAQ:NEOG) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded Neogen (NASDAQ:NEOG) stock from "buy" to "strong-buy," and Piper Sandler also raised its rating to "overweight" with a price target increase to $14. Despite these upgrades, the overall analyst consensus remains "Hold" with a target of $12.00. Neogen recently surpassed quarterly earnings expectations, reporting $0.09 EPS against a $0.06 estimate and $225.3 million in revenue against $212.35 million expected.
A business transformation plan will take center stage at Neogen's Oct. 7 event
Neogen Corporation announced it will host an Investor Day on October 7, 2026, in New York City. The event will focus on the company's strategic transformation, providing details on its commercial prowess, innovation, and operational excellence to drive sustainable financial performance. Executives will discuss plans for long-term profitable growth and value creation for shareholders.
The Manufacturers Life Insurance Company Takes $956,000 Position in Neogen Corporation $NEOG
The Manufacturers Life Insurance Company recently acquired a new position in Neogen Corporation, purchasing 106,372 shares valued at approximately $956,000. This move comes as institutional investors now own 96.73% of Neogen's stock, and analysts maintain a "Hold" consensus rating with an average price target of $12.00, despite a recent upgrade from Piper Sandler. Neogen's latest quarterly earnings exceeded expectations, posting $0.09 EPS on revenues of $225.3 million.
Jupiter Topco LLC Buys New Stake in Neogen Corporation $NEOG
Jupiter Topco LLC has acquired a new stake in Neogen Corporation, purchasing 101,525 shares valued at approximately $911,000 during the second quarter. Neogen (NASDAQ:NEOG) reported strong quarterly earnings, beating analyst estimates with $0.09 EPS and $225.3 million in revenue. Despite mixed analyst sentiment with an average "Hold" rating, Piper Sandler upgraded the stock to "overweight" with a raised price target of $14.00.
Legal & General Group Plc Makes New Investment in Neogen Corporation $NEOG
Legal & General Group Plc has made a new investment in Neogen Corporation, purchasing over 500,000 shares valued at approximately $4.5 million. This investment positions Legal & General as a significant stakeholder, owning about 0.23% of Neogen. The move comes as Neogen reports better-than-expected quarterly earnings and receives mixed but improving analyst ratings, with its stock trading near its 52-week high.
Is Neogen (NEOG) Already Overvalued After A 106% Run?
Neogen (NEOG) stock has seen a 106% increase over the past year, leading to concerns about its current valuation. While its P/S ratio is similar to the broader medical equipment industry, Simply Wall St's analysis suggests it's overvalued based on its fundamentals and risk profile. The article questions whether Neogen's future revenue growth and margin improvements can justify its current rich price, advising investors to consider the limited room for error.
Bank of New York Mellon Corp Invests $11.40 Million in Neogen Corporation $NEOG
Bank of New York Mellon Corp has acquired a new stake of 1.27 million shares in Neogen Corporation, valued at approximately $11.4 million. This investment represents about 0.58% of Neogen, with institutional investors collectively holding 96.73% of the company's stock. Neogen recently exceeded earnings and revenue estimates, though analyst sentiment remains mixed with a consensus "Hold" rating.
Neogen Surges 102.8% in a Year: What's Driving the Rally?
Neogen Corporation (NEOG) has seen a significant 102.8% increase in its stock price over the past year, driven by strong R&D efforts, including new product launches and increased fiscal 2027 R&D spending. The company's Food Safety and Animal Safety segments show healthy growth, further bolstered by its 2022 merger with 3M's Food Safety business. Despite potential risks from foreign currency exposure and intense competition, analysts maintain a positive outlook, with a Zacks Rank #2 (Buy) recommendation.
Jefferies Financial Group Inc. Acquires Shares of 163,853 Neogen Corporation $NEOG
Jefferies Financial Group Inc. has acquired a new position of 163,853 shares in Neogen Corporation, valued at approximately $1.47 million, bringing institutional ownership to 96.73%. Neogen reported better-than-expected earnings of $0.09 per share and revenue of $225.3 million. Analyst sentiment is improving, with Piper Sandler upgrading the stock to "overweight" and raising its price target to $14, though the overall consensus remains a "Hold" with an average price target of $12.
Brasada Capital Management LP Makes New $3.06 Million Investment in Neogen Corporation $NEOG
Brasada Capital Management LP has made a new $3.06 million investment in Neogen Corporation (NASDAQ:NEOG), acquiring 340,305 shares. This comes as Neogen reported better-than-expected quarterly earnings and revenue, leading to improved analyst sentiment with Piper Sandler upgrading the stock to "overweight." Despite positive adjustments to future EPS forecasts by Zacks Research, the broader analyst consensus for Neogen remains "Hold" with an average price target of $12.00.
Deutsche Bank AG Acquires Shares of 376,245 Neogen Corporation $NEOG
Deutsche Bank AG has acquired a new stake of 376,245 shares in Neogen Corporation, valued at approximately $3.38 million. This comes as Neogen exceeded quarterly earnings and revenue expectations, reporting $0.09 adjusted EPS against a $0.06 consensus. Analyst sentiment is improving but remains mixed, with Piper Sandler upgrading the stock to "overweight" with a $14 price target, while the broader consensus is "Hold" with a $12 target.
American Capital Management Inc. Buys New Position in Neogen Corporation $NEOG
American Capital Management Inc. has acquired a new stake in Neogen Corporation, purchasing 133,457 shares valued at approximately $1.2 million, representing 0.06% of the company. This comes as institutional investors collectively own 96.73% of NEOG, and analysts maintain a mixed but improving outlook, with Piper Sandler upgrading the stock to "overweight." Neogen also exceeded its quarterly earnings and revenue expectations, despite a slight year-over-year revenue decline and negative net margin.
Piper Sandler upgrades Neogen stock rating on turnaround progress
Piper Sandler upgraded Neogen (NASDAQ:NEOG) to Overweight from Neutral, raising its price target to $14.00 due to improved performance, led by a new management team, accelerated Food Safety growth, and better adjusted EBITDA margins. Despite significant year-to-date and past-year returns, InvestingPro analysis suggests the stock might be overvalued relative to its Fair Value estimate. The upgrade follows Neogen's strong fiscal fourth-quarter results, surpassing Wall Street expectations with adjusted earnings of $0.09 per share and revenue of $225.3 million.
168,254 Shares in Neogen Corporation $NEOG Acquired by Expect Equity LLC
Expect Equity LLC recently acquired 168,254 shares of Neogen Corporation (NASDAQ:NEOG) for approximately $1.51 million, representing about 0.08% of the company, with institutional investors now owning 96.73% of the stock. Despite a consensus "Hold" rating from analysts, Neogen's Q2 earnings of $0.09 per share beat estimates, and revenue exceeded forecasts. The company’s stock opened at $11.64, with a 12-month range of $4.90 to $12.85.
Piper Sandler upgrades Neogen stock rating on turnaround progress By Investing.com
Piper Sandler upgraded Neogen (NASDAQ:NEOG) to Overweight from Neutral, raising its price target to $14.00, citing improved performance, accelerating Food Safety growth, and a new management team. The firm noted Neogen's improved adjusted EBITDA margins, positive free cash flow, and a more disciplined commercial strategy, indicating the company has moved beyond stabilization and is entering a period of sustainable profitable growth. This upgrade aligns with Neogen's strong fiscal fourth-quarter results, where it surpassed Wall Street estimates for earnings and revenue, driven by core growth and increased food safety sales.
Cibc World Market Inc. Buys Shares of 3,500,500 Neogen Corporation $NEOG
CIBC World Market Inc. recently acquired 3,500,500 shares of Neogen Corporation ($NEOG) in the second quarter, a new position valued at approximately $31.5 million, representing 1.61% of the company. Institutional investors now collectively own 96.73% of Neogen. The company reported strong quarterly earnings, surpassing analyst estimates, and currently holds a consensus "Hold" rating from analysts with an average price target of $11.67.
Heartland Advisors Inc. Buys Shares of 1,000,000 Neogen Corporation $NEOG
Heartland Advisors Inc. has acquired 1 million shares of Neogen Corporation (NASDAQ:NEOG), valued at approximately $8.99 million, representing 0.46% of the company. This comes as Neogen's shares increased by 1% to $11.95, nearing its 52-week high, and the company reported strong quarterly earnings and revenue that surpassed analyst expectations. While analyst sentiment is mixed with a consensus "Hold" rating, some analysts have upgraded the stock and raised price targets.
Neogen (NEOG) asks investors to boost equity awards and ESPP pool
Neogen Corporation (NEOG) is seeking shareholder approval to increase its Omnibus Incentive Plan by 11.35 million shares to a total of 31.35 million shares, and to add 5 million shares to its Employee Stock Purchase Plan (ESPP), bringing its capacity to 6 million shares. The proposals will be voted on at the virtual annual meeting scheduled for October 1, 2026. The company reported a 3% GAAP revenue decline in fiscal year 2026 but a 2% core revenue growth, alongside significant operational improvements like a 24% reduction in inventory and a $100 million reduction in net debt.
Why Did Neogen (NEOG) Lose A Board Member And What Changes Now?
Neogen Corporation (NEOG) announced the resignation of board member Thierry Bernard. This change adjusts the composition of Neogen's board, which is crucial for overseeing the company's focus on food and animal safety, integration challenges, and margin improvements. While Bernard's departure slightly weakens governance, the company's narrative is also driven by regulatory tailwinds and operational fixes, raising questions about the refreshed board's ability to match peers in specialized experience.
Neogen Corp CEO Mikheal Nassif Executes RSU Tax Withholding on August 19, 2026
Mikheal Nassif, CEO and Director of Neogen Corp, had 20,397 restricted stock units (RSUs) withheld on August 19, 2026, to cover tax obligations upon vesting. This transaction, detailed in a Form 4 filing, involved shares valued at $11.87 each. Following the tax withholding, Nassif retains ownership of 25,655 restricted stock units.
Neogen Corp (NEOG) CAO has stock withheld to cover RSU taxes
Neogen Corp's Chief Accounting Officer, John Patrick Moylan, had 2,365 shares of NEOG common stock withheld to cover tax liabilities when restricted stock units (RSUs) vested on August 19, 2026. This transaction, valued at $11.87 per share for tax purposes, resulted in Moylan directly holding 29,331 shares afterward. The event is categorized as a tax-withholding disposition rather than an open-market sale.
Neogen (NEOG) CEO uses 20K shares to cover RSU taxes
Neogen CEO Mikheal Nassif had 20,397 shares of common stock withheld on August 19, 2026, to cover tax obligations related to vested Restricted Stock Units (RSUs). This transaction, valued at $11.87 per share, was an F-code transaction for tax withholding and not an open-market sale. Following this, Nassif directly holds 25,655 shares of NEOGEN common stock.
Neogen Corporation (NASDAQ:NEOG) Given Average Rating of "Hold" by Brokerages
Neogen Corporation (NASDAQ:NEOG) has received a consensus "Hold" rating from five research firms, with an average 1-year price target of $11.6667. The company recently reported strong quarterly earnings, beating analyst estimates for both EPS and revenue. Institutional investors have also been adjusting their positions in Neogen stock.
